However, this procedure has two major shortcomings: (a) it is invasive and thus cannot be used to re-assess or monitor the BRAF gene status overtime; (b) a significant number of mutation-positive patients are missed due to tumor genomic heterogeneity4. This evidence concerns the gene BRAF and neoplasm.